News Sentiment

PROK sentiment intelligence

ProKidney Corp. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.62 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-8.0% over one week, -11.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

ProKidney Corp. (PROK) Q1 2026 Earnings: In-Line EPS, Pre-Revenue Progress Drives Modest Stock Gain - Consensus Miss Rate

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -8.0% Price reacting lower
Trend fit Trend inactive -11.5% over four weeks
Fair value -32.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 33
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 10
TradingView 5
dars.gov.et 4
simplywall.st 3
TradingKey 2
Kalkine Media 2
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 17
Balance sheet 2
Regulatory and legal 1
Macro sensitivity 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Stock Titan Direct company coverage

ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike

ProKidney (NASDAQ: PROK) Chief Technical Officer Kenneth Thomas Locke was granted 750,000 employee stock options with an exercise price of $1.89 per share, expiring on July 1, 2036. This compensation-related award vests 25% on July 1, 2027, with the remaining 75% vesting monthly

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:11
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of ProKidney Corp. Class A – BMV:PROK

The article displays the "Price to earnings forward" metric for ProKidney Corp. Class A (BMV:PROK) on TradingView. It shows that for the specified period, the value is not available, with "No trades" indicated. The content primarily consists of navigation and boilerplate financia

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 19:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK

This article displays the title "Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK" and indicates that the market for ProKidney Corp. Class A (PROK) on the Mexican Stock Exchange is closed with no trades. It appears to be a stub or a section of a financial da

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 11:40
Source
TradingView
TradingView Direct company coverage

ProKidney Corp. Class A Actuals & Estimates (NASDAQ:PROK)

This article provides an overview of ProKidney Corp. (PROK) stock, including its current price, market capitalization, and historical performance. It also details financial estimates, analyst forecasts for future price targets, and information on past earnings reports and upcomin

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
Stock Titan Direct company coverage

ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stock

ProKidney's Chief Legal Officer, Todd C. Girolamo, converted 163,857 paired Class B Common Stock and common units into an equal number of Class A Common Stock on June 12, 2026, at $0.00 per share. This non-cash derivative conversion increased his direct Class A holdings to 327,71

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 21:32
Source
Stock Titan
The Manila Times Direct company coverage

ProKidney Appoints Kenneth Locke as Chief Technical Officer

ProKidney (Nasdaq: PROK), a late clinical-stage cell therapy company focused on chronic kidney disease, has appointed Kenneth Locke as its new Chief Technical Officer. Locke brings over 25 years of experience in Chemistry, Manufacturing and Controls (CMC) and Supply Chain, which

Tone
Positive 74/100
Event
Macro sensitivity
Published
05 Jun 2026 14:39
Source
The Manila Times
Stock Titan Direct company coverage

PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award

PROKIDNEY CORP. director Brian JG Pereira was granted 135,000 director stock options as part of the company's non-employee director compensation policy. These options have an exercise price of $1.81 per share, expire on May 28, 2036, and will vest in full on the earlier of the on

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

ProKidney (PROK) director receives 135,000 stock options grant as compensation

ProKidney (PROK) director Jennifer A. Fox received a grant of 135,000 stock options as part of her non-employee director compensation. These options allow her to purchase Class A Common Stock at an exercise price of $1.81 per share and will vest fully on the earlier of one year f

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation

PROKIDNEY CORP. (PROK) director Jose Ignacio Jimenez Santos received a grant of 135,000 stock options as part of the company’s non-employee director compensation policy. These options have an exercise price of $1.81 per share, expire on May 28, 2036, and will vest fully on the ea

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

PROKIDNEY CORP. (PROK) director receives 135,000 stock options grant

PROKIDNEY CORP. director Alan Lotvin was granted 135,000 stock options as part of his non-employee director compensation. These options allow him to purchase Class A Common Stock at an exercise price of $1.81 per share, vesting fully on the earlier of one year from the grant date

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 19:38
Source
Stock Titan
Stock Titan Direct company coverage

ProKidney (PROK) director awarded 135K stock options as compensation

ProKidney (PROK) director William F. Doyle was granted 135,000 stock options as part of his non-employee director compensation. These options allow him to purchase Class A Common Stock at an exercise price of $1.81 per share and will vest fully on the earlier of one year from the

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 19:38
Source
Stock Titan
AlphaStreet Direct company coverage

ProKidney Releases Q1 2026 Financial Results

ProKidney Corp. (PROK) reported a wider loss for the first quarter of 2026, with a loss per share of $0.14 and a net loss of $42.6 million. The clinical-stage biotechnology company's revenue decreased slightly to $226,000, reflecting its focus on cell therapy development for chro

Tone
Negative 38/100
Event
Earnings
Published
16 May 2026 22:13
Source
AlphaStreet
Stock Titan Direct company coverage

[8-K] PROKIDNEY CORP. Reports Material Event

ProKidney Corp. (PROK) reported a net loss of $42.6 million for Q1 2026 as the company continues to invest heavily in its lead cell therapy, rilparencel, for chronic kidney disease. The company maintains a strong liquidity position with $224.9 million in cash, expected to fund op

Tone
Positive 62/100
Event
Balance sheet
Published
15 May 2026 22:13
Source
Stock Titan
Stock Titan Direct company coverage

ProKidney (NASDAQ: PROK) Q1 2026 loss, R&D spend and cash runway to 2027

ProKidney (PROK) reported a net loss of $20.0 million for Q1 2026, an increase from $16.7 million in Q1 2025, primarily due to higher research and development expenses. R&D spending rose to $33.8 million, driven by the ongoing Phase 3 PROACT 1 clinical trial for rilparencel, aime

Tone
Negative 38/100
Event
Balance sheet
Published
15 May 2026 22:13
Source
Stock Titan
TradingView Direct company coverage

PROKIDNEY CORP. 1Q 2026: Revenue $0.226M, EPS $(0.14) — 10-Q Summary

PROKIDNEY CORP. reported its first-quarter 2026 results, showing a revenue of $0.226 million and a net loss per share of $(0.14), which is worse than the prior year's figures. The company highlighted ongoing Phase 3 clinical trials, increased R&D spending, and a cash runway exten

Tone
Negative 36/100
Event
Earnings
Published
15 May 2026 15:41
Source
TradingView
GlobeNewswire Direct company coverage

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney reported its first-quarter 2026 financial results, highlighting that it is on track to complete enrollment for the Phase 3 PROACT 1 clinical trial for rilparencel by mid-2026, with pivotal topline results expected in Q2 2027. The company ended Q1 2026 with $224.9 millio

Tone
Positive 71/100
Event
Earnings
Published
15 May 2026 11:45
Source
GlobeNewswire